Clinical Trials · NCT06518837
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Rutgers, The State University of New Jersey
- Enrollment
- 40
- Start date
- Oct 2024
- Locations
- 7 sites, United States
- Primary endpoint
- Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction)